Caracterización de pacientes con microcarcinoma papilar de tiroides en el Hospital de Clínicas (UDELAR) en los últimos 10 años

Gabriela Mintegui; Florencia Casamayou; Claudia Arciénega; Beatriz Mendoza; Alvaro Ronco

doi:10.29193/RMU.37.4.4

Authors

Gabriela Mintegui Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Clínica de Endocrinología y Metabolismo, Profesora Adjunta
Florencia Casamayou Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Especialista de Endocrinología y Metabolismo
Claudia Arciénega Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Especialista de Endocrinología y Metabolismo
Beatriz Mendoza Universidad de la República, Facultad de Medicina, Hospital de Clínicas, Clínica de Endocrinología y Metabolismo, Profesora
Alvaro Ronco CLAEH, Facultad de Medicina, Profesor asociado de Oncología

DOI:

https://doi.org/10.29193/RMU.37.4.4

Keywords:

PAPILLARY THYROID MICROCARCINOMA

Abstract

Introduction: papillary thyroid microcarcima (PTMC) is a tumour <1 cm in size, indolent and with incidental or asymptomatic diagnostic. Recently, the incidence of PTMC increased as a result of higher ultrasound detection of nonpalpable nodes, although mortality rates remain stable, with high survival in the long-term.
Objective: to characterize patients with PTMC at the Endocrinology and Metabolism Department of the Clinicas University Hospital in the 2008-2018 decade.
Method: observational, transversal, retrospective and analytical study. Medical records filed and policlinic records of patients who were seen in our service since June, 2008 and June, 2018 were reviewed. The number of patients assisted in the hospital between 1978 and 2008 was found, to estimate incidence and annual casuistic. Statistical analysis of variables and tendencies was performed.
Results: 42 (22%) out of 139 patients with poorly differentiated thyroid carcinoma (PDTC) had papillary thyroid microcarcinoma. In the last 40 years, hospital incidence of PTMC has increased (average = 4,2 cases/year), 88% of which were female patients. 69% of diagnostics were done by thyroid fine-needle aspirate cytology (FNAC); 57% were single focal and 43% multifocal. There was a significant association between multifocality and capsule invasion. 84% of cases did not evidence lymph node metastases. In 55% of cases postoperative radioactive iodine therapy was applied.
Conclusions: the incidence of PTMC increased, mainly in women. Diagnosis prior to surgery was mainly done by thyroid FNAC. Capsular invasion was associated to multifocality. 16% evidence lymph node metastases upon diagnosis. Complete thyroidectomy was done in most cases, followed by radioactive iodine therapy un 55% of cases.

References

1) Sugitani I, Toda K, Yamada K, Yamamoto N, Ikenaga M, Fujimoto Y. Three distinctly different kinds of papillary thyroid microcarcinoma should be recognized: our treatment strategies and outcomes. World J Surg 2010; 34(6):1222-31.
2) Ito Y, Miyauchi A, Inoue H, Fukushima M, Kihara M, Higashiyama T, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 2010; 34(1):28-35.
3) Pitoia F, Califano I, Vázquez A, Faure E, Gauna A, Orlandi A, et al. Consenso intersocietario sobre tratamiento y seguimiento de pacientes con cáncer diferenciado de tiroides. Rev Argent Endocrinol Metab 2014; 51(2):85-118.
4) Harach H, Franssila K, Wasenius V. Occult papillary carcinoma of the thyroid. A “normal” finding in Finland. A systematic autopsy study. Cancer 1985; 56(3):531-8.
5) Fukunaga F, Yatani R. Geographic pathology of occult thyroid carcinomas. Cancer 1975; 36(3):1095-9.
6) Samson R. Prevalence and significant of occult thyroid cancer. En: DeGroot L, ed. Radiation-associated thyroid carcinoma. New York: Grune & Stratton, 1997:137-53.
7) Thorvaldsson S, Tulinius H, Björnsson J, Bjarnason O. Latent thyroid carcinoma in Iceland at autopsy. Pathol Res Pract 1992; 188(6):747-50.
8) Bernet V. Approach to the patient with incidental papillary microcarcinoma. J Clin Endocrinol Metab 2010; 95(8):3586- 92.
9) Brito J, Ito Y, Miyauchi A, Tuttle R. A clinical framework to facilitate risk stratification when considering an active surveillance alternative to immediate biopsy and surgery in papillary microcarcinoma. Thyroid 2016; 26(1):144-9.
10) Ito Y, Oda H, Miyauchi A. Insights and clinical questions about the active surveillance of low-risk papillary thyroid microcarcinomas. Endocr J 2016; 63(4):323-8.
11) Ito Y, Miyauchi A, Kihara M, Higashiyama T, Kobayashi K, Miya A. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation. Thyroid 2014; 24(1):27-34.
12) Sampson R, Key C, Buncher C, Iijima S. Thyroid carcinoma in Hiroshima and Nagasaki: I. Prevalence of thyroid carcinoma at autopsy. JAMA 1969; 209(1):65-70.
13) Mehrdad K, Ghodratollah M, Tarhini M, Ali F. Papillary thyroid microcarcinoma with large and cystic neck metastasis: report of a case and review of articles. J Res Med Sci 2006; 11(5):334-8.
14) Lang W, Borrusch H, Bauer L. Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies. Am J Clin Pathol 1988; 90(1):72-6.
15) Davies L, Welch H. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295(18):2164-7.
16) Davies L, Welch H. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg 2014; 140(4):317-22.
17) Ahn H, Kim H, Welch H. Korea’s thyroid-cancer “epidemic”: screening and overdiagnosis. N Engl J Med 2014; 371(19):1765-7.
18) Orellano P, Cortez E. Microcarcinoma papilar de tiroides: caracterización clínica patológica período 1977-2005. Hospital de Clínicas. Montevideo: Facultad de Medicina, 2005. Disponible en: https://endosuem.org.uy/wp-content/uploads/ 2010/10/microcarcinoma_papilar_tiroides_ptmc.pdf. [Consulta: 7 marzo 2021].
19) Olen E, Klinck G. Hyperthyroidism and thyroid cancer. Arch Pathol 1966; 81(6):531-5.
20) Carlini M, Giovannini C, Mercadante E, Castaldi F, Dell’Avanzato R, Zazza S. Incidental thyroid microcarcinoma in benign thyroid disease: incidence in a total of 100 consecutive thyroidectomies. Chir Ital 2006; 58(4):441-7.
21) Leenhardt L, Grosclaude P, Chérié-Challine L. Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004; 14(12):1056-60.
22) Burgess J, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid 2006; 16(1):47-53.
23) Grodski S, Delbridge L. An update on papillary microcarcinoma. Curr Opin Oncol 2009; 21(1):1-4. doi: 10.1097/ CCO.0b013e32831a9a82.
24) Baudin E, Travagli J, Ropers J, Mancusi F, Bruno-Bossio G, Caillou B, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998; 83(3):553-9.
25) Chow S, Law S, Chan J, Au S, Yau S, Lau W. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer 2003; 98(1):31-40.
26) Anastasilakis A, Polyzos S, Makras P, Kampas L, Valeri R, Kyriakoulis D, et al. Papillary thyroid microcarcinoma presenting as lymph node metastasis—a diagnostic challenge: case report and systematic review of literature. Hormones (Athens) 2012; 11(4):419-27.
27) Malandrino P, Pellegriti G, Attard M, Violi M, Giordano C, Sciacca L, et al. Papillary thyroid microcarcinomas: a comparative study of the characteristics and risk factors at presentation in two cancer registries. J Clin Endocrinol Metab 2013; 98(4):1427-34.
28) Roti E, degli Uberti E, Bondanelli M, Braverman L. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol 2008; 159(6):659-73.
29) Mazzaferri E. Management of low-risk differentiated thyroid cancer. Endocr Pract 2007; 13(5):498-512.
30) Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26(1):1-133. doi: 10.1089/thy.2015.0020.